840 results match your criteria: "Laura and Isaac Perlmutter Cancer Center[Affiliation]"
Nat Commun
May 2023
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.
Cold Spring Harb Protoc
May 2024
Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York 10016, USA
Synthetic binding proteins are human-made binding proteins that use non-antibody proteins as the starting scaffold. Molecular display technologies, such as phage display, enable the construction of large combinatorial libraries and their efficient sorting and, thus, are crucial for the development of synthetic binding proteins. Monobodies are the founding system of a set of synthetic binding proteins based on the fibronectin type III (FN3) domain.
View Article and Find Full Text PDFBiology (Basel)
March 2023
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
circRNAs constitute a novel class of RNA, generally considered as non-coding RNAs; nonetheless, their coding potential has been under scrutiny. In this work, we systematically explored the predicted proteins of more than 160,000 circRNAs detected by exome capture RNA-sequencing and collected in the MiOncoCirc pan-cancer compendium, including normal and cancer samples from different types of tissues. For the functional evaluation, we compared their primary structure and domain composition with those derived from the same linear mRNAs.
View Article and Find Full Text PDFRadiology
May 2023
From the Department of Medical Imaging, University Medical Imaging Toronto, University of Toronto, 585 University Ave, Toronto, ON, Canada M5G 2N2 (K.H.); Department of Radiology, Hospital Sirio-Libanes, São Paulo, Brazil (J.A.B.A.F., C.H.N.); Radiological and Diagnostic Imaging Society of São Pau
Cancer Discov
July 2023
Department of Pathology, NYU Grossman School of Medicine, New York, New York.
Unlabelled: BH3 mimetics are used as an efficient strategy to induce cell death in several blood malignancies, including acute myeloid leukemia (AML). Venetoclax, a potent BCL-2 antagonist, is used clinically in combination with hypomethylating agents for the treatment of AML. Moreover, MCL1 or dual BCL-2/BCL-xL antagonists are under investigation.
View Article and Find Full Text PDFNat Commun
April 2023
Division of Genomics and Precision Medicine, Department of Medicine, University of California San Diego (UCSD), San Diego, USA.
Ependymoma is a tumor of the brain or spinal cord. The two most common and aggressive molecular groups of ependymoma are the supratentorial ZFTA-fusion associated and the posterior fossa ependymoma group A. In both groups, tumors occur mainly in young children and frequently recur after treatment.
View Article and Find Full Text PDFStem Cell Reports
May 2023
Laboratory of Synthetic Embryology, the Rockefeller University, New York, NY, USA. Electronic address:
Although lung disease is the primary clinical outcome in COVID-19 patients, how SARS-CoV-2 induces lung pathology remains elusive. Here we describe a high-throughput platform to generate self-organizing and commensurate human lung buds derived from hESCs cultured on micropatterned substrates. Lung buds resemble human fetal lungs and display proximodistal patterning of alveolar and airway tissue directed by KGF.
View Article and Find Full Text PDFSci Adv
April 2023
Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY 10016, USA.
Pancreatic ductal adenocarcinoma (PDAC) cells maintain a high level of autophagy, allowing them to thrive in an austere microenvironment. However, the processes through which autophagy promotes PDAC growth and survival are still not fully understood. Here, we show that autophagy inhibition in PDAC alters mitochondrial function by losing succinate dehydrogenase complex iron sulfur subunit B expression by limiting the availability of the labile iron pool.
View Article and Find Full Text PDFPurpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB-C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year efficacy and biomarker findings.
Patients And Methods: Patients with resected stage IIIB-C/IV melanoma were stratified by stage and baseline programmed death cell ligand 1 (PD-L1) expression and received nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks, both intravenously for 1 year until disease recurrence, unacceptable toxicity, or withdrawal of consent.
Blood Cancer Discov
July 2023
Department of Pathology and Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, New York.
Unlabelled: Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia.
View Article and Find Full Text PDFNatl Sci Rev
April 2023
State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and squamous pathologies, harbors strong plasticity and is significantly associated with poor prognosis. We established an up-to-date comprehensive genomic and transcriptomic landscape of LUAS in 109 Chinese specimens and demonstrated LUAS development via adeno-to-squamous transdifferentiation. Unsupervised transcriptomic clustering and dynamic network biomarker analysis identified an inflammatory subtype as the critical transition stage during LUAS development.
View Article and Find Full Text PDFJ Transl Med
March 2023
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, 522 First Avenue, New York City, NY, 10016, USA.
Radiology
May 2023
From the Department of Radiology, New York University Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center, 160 E 34th St, 3rd Floor, New York, NY 10016.
J Thorac Oncol
July 2023
Division of Hematology and Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York.
Introduction: In KRAS-mutant NSCLC, co-occurring alterations in LKB1 confer a negative prognosis compared with other mutations such as TP53. LKB1 is a tumor suppressor that coordinates several signaling pathways in response to energetic stress. Our recent work on pharmacologic and genetic inhibition of histone deacetylase 6 (HDAC6) revealed the impaired activity of numerous enzymes involved in glycolysis.
View Article and Find Full Text PDFNeurooncol Adv
February 2023
Harold C. Simmons Comprehensive Cancer Center and the Department of Pediatrics, University of Texas Southwestern Medical School, Dallas, TX, USA.
Background: Preclinical studies have suggested that mTOR pathway signaling may be a potential therapeutic target for childhood ependymoma.
Methods: A phase II clinical trial (ClinicalTrials.gov identifier: NCT02155920) of single-agent everolimus was performed to test the hypothesis that mTOR pathway inhibition would result in tumor responses for children with recurrent and/or progressive ependymomas.
Mol Cell
April 2023
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address:
Highly coordinated changes in gene expression underlie T cell activation and exhaustion. However, the mechanisms by which such programs are regulated and how these may be targeted for therapeutic benefit remain poorly understood. Here, we comprehensively profile the genomic occupancy of mSWI/SNF chromatin remodeling complexes throughout acute and chronic T cell stimulation, finding that stepwise changes in localization over transcription factor binding sites direct site-specific chromatin accessibility and gene activation leading to distinct phenotypes.
View Article and Find Full Text PDFNat Immunol
April 2023
Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York University Langone Health, New York, NY, USA.
Nat Immunol
April 2023
Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York University Langone Health, New York, NY, USA.
Antigen-specific CD8 T cell accumulation in tumors is a prerequisite for effective immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we show that tumor-associated lymphatic vessels control T cell exit from tumors via the chemokine CXCL12, and intratumoral antigen encounter tunes CXCR4 expression by effector CD8 T cells. Only high-affinity antigen downregulates CXCR4 and upregulates the CXCL12 decoy receptor, ACKR3, thereby reducing CXCL12 sensitivity and promoting T cell retention.
View Article and Find Full Text PDFCell Rep
January 2023
Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA. Electronic address:
TET2 haploinsufficiency is a driving event in myeloid cancers and is associated with a worse prognosis in patients with acute myeloid leukemia (AML). Enhancing residual TET2 activity using vitamin C increases oxidized 5-methylcytosine (mC) formation and promotes active DNA demethylation via base excision repair (BER), which slows leukemia progression. We utilize genetic and compound library screening approaches to identify rational combination treatment strategies to improve use of vitamin C as an adjuvant therapy for AML.
View Article and Find Full Text PDFFront Oncol
February 2023
Harvard Medical School, Department of Medicine, Boston, MA, United States.
Radiother Oncol
May 2023
Department of Radiation Oncology, ThedaCare Regional Medical Center, Appleton, WI, USA.
Introduction: Radiation-induced brachial plexopathy (RIBP), resulting in symptomatic motor or sensory deficits of the upper extremity, is a risk after exposure of the brachial plexus to therapeutic doses of radiation. We sought to model dosimetric factors associated with risks of RIBP after stereotactic body radiotherapy (SBRT).
Methods: From a prior systematic review, 4 studies were identified that included individual patient data amenable to normal tissue complication probability (NTCP) modelling after SBRT for apical lung tumors.
J Exp Med
May 2023
Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health , New York, NY, USA.
bioRxiv
February 2023
Department of Neurosurgery, NYU Grossman School of Medicine, New York, NY 10016, USA.
GPR133 (ADGRD1) is an adhesion G protein-coupled receptor that signals through Gαs and is required for growth of glioblastoma (GBM), an aggressive brain malignancy. The regulation of GPR133 signaling is incompletely understood. Here, we use proximity biotinylation proteomics to identify ESYT1, a Ca-dependent mediator of endoplasmic reticulum-plasma membrane bridge formation, as an intracellular interactor of GPR133.
View Article and Find Full Text PDFLancet Gastroenterol Hepatol
March 2023
Division of Hematology and Oncology, Department of Medicine, University of Florida Health Cancer Center, Gainesville, FL 32608, USA. Electronic address: